Biogen Likely To Get Priority Review For Aducanumab, Says Jefferies
July 08, 2020 at 10:38 AM EDT
Biogen's completed Biologics License Application submission for aducanumab "finally begins the big journey of what will be a hotly debated FDA review," Jefferies analyst Michael Yee tells investors in a research note.
